$47.97 Million in Sales Expected for OraSure Technologies, Inc. (OSUR) This Quarter

Equities research analysts expect OraSure Technologies, Inc. (NASDAQ:OSUR) to post sales of $47.97 million for the current quarter, Zacks reports. Two analysts have made estimates for OraSure Technologies’ earnings, with the highest sales estimate coming in at $50.45 million and the lowest estimate coming in at $45.50 million. OraSure Technologies posted sales of $35.50 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 35.1%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, February 14th.

According to Zacks, analysts expect that OraSure Technologies will report full-year sales of $47.97 million for the current financial year, with estimates ranging from $160.60 million to $165.48 million. For the next fiscal year, analysts forecast that the company will report sales of $175.78 million per share, with estimates ranging from $173.00 million to $178.55 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow OraSure Technologies.

OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 EPS for the quarter, hitting analysts’ consensus estimates of $0.09. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The company had revenue of $42.30 million for the quarter, compared to the consensus estimate of $40.87 million. During the same period in the previous year, the firm earned $0.11 earnings per share. OraSure Technologies’s quarterly revenue was up 31.0% compared to the same quarter last year.

A number of equities analysts have commented on OSUR shares. Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Wednesday, September 20th. Canaccord Genuity reaffirmed a “buy” rating and set a $22.00 target price on shares of OraSure Technologies in a research note on Tuesday, September 19th. Jefferies Group reaffirmed a “buy” rating and set a $23.00 target price on shares of OraSure Technologies in a research note on Friday, October 20th. BidaskClub raised shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Thursday, December 21st. Finally, ValuEngine downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. OraSure Technologies currently has an average rating of “Buy” and an average price target of $19.65.

In related news, Director Mara G. Aspinall purchased 5,000 shares of the company’s stock in a transaction on Tuesday, November 7th. The stock was acquired at an average cost of $14.23 per share, for a total transaction of $71,150.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at $71,150. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 6.40% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. State Street Corp increased its position in shares of OraSure Technologies by 6.9% during the second quarter. State Street Corp now owns 1,639,620 shares of the medical instruments supplier’s stock valued at $28,305,000 after acquiring an additional 106,326 shares during the last quarter. USA Financial Portformulas Corp increased its position in shares of OraSure Technologies by 31.0% during the second quarter. USA Financial Portformulas Corp now owns 56,653 shares of the medical instruments supplier’s stock valued at $978,000 after acquiring an additional 13,421 shares during the last quarter. 361 Capital LLC increased its position in shares of OraSure Technologies by 59.9% during the second quarter. 361 Capital LLC now owns 26,974 shares of the medical instruments supplier’s stock valued at $466,000 after acquiring an additional 10,107 shares during the last quarter. Voya Investment Management LLC increased its position in shares of OraSure Technologies by 179.4% during the second quarter. Voya Investment Management LLC now owns 78,325 shares of the medical instruments supplier’s stock valued at $1,352,000 after acquiring an additional 50,287 shares during the last quarter. Finally, Macquarie Group Ltd. acquired a new stake in shares of OraSure Technologies during the second quarter valued at about $892,000. Institutional investors and hedge funds own 94.43% of the company’s stock.

Shares of OraSure Technologies (NASDAQ:OSUR) traded up $0.75 during mid-day trading on Friday, reaching $21.22. 445,070 shares of the company’s stock were exchanged, compared to its average volume of 569,127. OraSure Technologies has a one year low of $8.39 and a one year high of $23.01. The stock has a market capitalization of $1,290.00, a P/E ratio of 40.81, a PEG ratio of 4.44 and a beta of 1.27.

WARNING: “$47.97 Million in Sales Expected for OraSure Technologies, Inc. (OSUR) This Quarter” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://ledgergazette.com/2018/01/18/47-97-million-in-sales-expected-for-orasure-technologies-inc-osur-this-quarter.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply